Amgen, Inc. vs Hewlett Packard Enterprise Co — how do they compare? Amgen, Inc. trades at $415.89 (market cap $224.14B), while Hewlett Packard Enterprise Co trades at $56.69 (market cap $72.01B). The key difference: Amgen, Inc. is far larger — about 3.1× Hewlett Packard Enterprise Co's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | HPE | |
|---|---|---|
Market Cap | $224.14B | $72.01B |
Sector | Health | Technology |
52-Week High | $417.20 | $56.14 |
52-Week Low | $271.18 | $20.01 |
Enterprise Value | $267.45B | $87.96B |
Dividend Yield | 2.43% | 1.05% |
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
HPE stock trades at $56.32, up 3.02% with strong momentum following recent analyst upgrades. The company shows robust earnings beats in recent quarters with Q1 2026 EPS of $0.79 beating expectations of $0.535. Technical indicators suggest bullish momentum while fundamentals show revenue growth to $34.3B in 2025, though net income declined significantly to $57M. Recent Morgan Stanley upgrade highlights AI infrastructure strength.
Outlook remains positive with AI-driven growth potential, though elevated P/E ratio of 50.82 warrants caution. Key risks include competitive pressures in server markets and execution challenges. Analyst consensus price target of $69.81 offers 24% upside potential from current levels, supported by institutional buying interest.
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →